Right-to-try law
Right-to-try laws broadly are United States state laws and a federal law created with the intent to allow seriously ill patients access to experimental therapies (drugs, biologics, devices). Right-to-try 1.0 (RtT 1.0) allows terminally ill patients access to treatments that have completed Phase I testing but not been approved by the Food and Drug Administration (FDA) across the US, since a federal right-to-try law (RtT 1.0) passed in 2018, extending it across the USA. Right-to-try 2.0 (RtT 2.0) laws, AKA Individualized Treatments Acts, now passed in 17 states, expand patient access in two major ways: they include individuals with non-terminal, rare, or degenerative conditions, and they permit the use of individualized experimental therapies that have not completed Phase I testing.